Log in or Sign up for Free to view tailored content for your specialty!
Diabetes Education News
Semaglutide linked to lower suicidal ideation risk than other obesity, diabetes drugs
Adults receiving semaglutide as a type 2 diabetes or obesity medication have a lower risk for suicidal ideation than those who are using a drug that is not a GLP-1 receptor agonist, according to findings published in Nature Medicine.
Time in range, other CGM metrics linked to diabetic retinopathy risk in type 1 diabetes
Providers can use continuous glucose monitoring metrics as well as HbA1c to assess diabetic retinopathy risk for adults with type 1 diabetes, according to findings published in Diabetes Technology & Therapeutics.
Log in or Sign up for Free to view tailored content for your specialty!
Combination insulin icodec and semaglutide cuts HbA1c and body weight in type 2 diabetes
Once-weekly combination therapy of basal insulin icodec and semaglutide was noninferior to insulin glargine plus insulin aspart for lowering HbA1c among adults with type 2 diabetes, according to topline results from a phase 3a trial.
Automated insulin delivery system can now integrate with 15-day CGM sensor
People with diabetes using a 15-day continuous glucose monitor sensor can now integrate their CGM with an automated insulin delivery system, according to a press release.
Q&A: Increased awareness may boost uptake of inhaled insulin
A form of inhaled insulin has been available for adults with type 1 and type 2 diabetes for nearly a decade, but providers say many people are not aware that it may be a treatment option for them.
Lilly warns public not to use tirzepatide for cosmetic weight loss
Eli Lilly and Co. released an open letter stating its tirzepatide products should not be used for cosmetic weight loss and warning the public about the circulation of compounded and counterfeit tirzepatide.
Preconception perceived stress affects glucose levels during pregnancy
Pregnant women are more likely to have high glucose levels if they report worse psychological stress before conception, according to study findings published in Journal of the Endocrine Society.
At Issue: The implications of SELECT on CVD prevention in high-risk patients with obesity
The SELECT trial, which showed semaglutide, a GLP-1 receptor agonist also approved for diabetes, reduced CV events in people with overweight/obesity and CVD but no diabetes, was one of the most important developments in cardiology in 2023.
FDA warns adults with diabetes about counterfeit semaglutide products
The FDA is warning adults with diabetes to avoid using counterfeit semaglutide that may be circulating in the U.S. drug supply chain, according to a press release.
No HbA1c improvements for adults with type 2 diabetes exclusively using telemedicine
A group of adults with type 2 diabetes who used only telemedicine for endocrinology care did not have improvements in HbA1c over 2 years of follow-up, according to findings published in JAMA Network Open.
-
Headline News
CDC: 1 dead in multistate outbreak of E. coli linked to organic carrots
November 18, 20241 min read -
Headline News
Obesity drugs could help lower alcohol intake
November 18, 20243 min read -
Headline News
Pediatric asthma ‘potential source of cognitive difficulty’
November 18, 20242 min read
-
Headline News
CDC: 1 dead in multistate outbreak of E. coli linked to organic carrots
November 18, 20241 min read -
Headline News
Obesity drugs could help lower alcohol intake
November 18, 20243 min read -
Headline News
Pediatric asthma ‘potential source of cognitive difficulty’
November 18, 20242 min read